OSA Therapy

Types of OSA therapy:

  1. Adjunctive therapy

    • Avoid excessive alcohol and sedative use

    • Environment/allergen modification

    • Medical or pharmacological nasal therapy eg nasonex spray or nasal irrigation

    • Weight loss

    • Positional therapy

      • May reduce AHI by up to 10 events per hour

    • Myofunctional exercises

    • Sleep hygiene

  2. Mainstream therapy:

    • Positive airway pressure (PAP) - CPAP, BPAP

    • Mandibular advancement oral appliance

    • Surgery

  3. Combination therapy

Informed Consent

  • Valid consent to treatment means consent to treatment that is voluntarily given by a competent person based on full disclosure and understanding of information; and includes authorisation for a specific treatment plan by a specific health care provider

  • Informed consent is a person’s voluntary decision about healthcare that is made with knowledge and understanding of the benefits and risks involved

  • Good practice includes that you:

    • Provide information to patients in a way they can understand before asking for their consent 

    • Give the patient enough time to ask questions and make informed decisions

    • Act according to the patient’s capacity for decision-making and consent, including when caring for children and young people, based on their maturity and capacity to understand, and the nature of the proposed care

    • You should consider the need for the consent of a parent, carer, guardian or other substitute decision maker

    • Get informed consent from the patient or where the patient does not have the capacity, from their parent, carer, guardian or other substitute decision-maker before carrying out any examination or investigation,

      providing treatment (this may not be possible in an emergency), or involving patients in teaching or research

    • When obtaining informed consent you should include information on material risks and expected outcomes and take into account any advance care directive (or similar)

    • Get financial consent by discussing fees in a manner appropriate to the professional relationship and addressing the costs of all required services and get general agreement about the level of treatment to be provided, preferably before the service is provided

    • Inform your patients of the benefits, as well as associated costs or risks, when referring them for further investigation or treatment, which they may wish to clarify before proceeding

    • Document consent appropriately, including considering the need for written consent for procedures which are of higher risk or may result in serious injury or death

CPAP compliance:

  • Adequate CPAP compliance is benchmarked as > 4 hours per night for > 70% of nights (Kribbs et al 1993)

  • CPAP compliance tends to reduce over time

    • After 6 months 50% use CPAP > 4 hours per night

    • After 5 years 17% use CPAP > 4 hours per night

Oral appliance compliance:

  • After 3 months, use > 7 hours per night

  • After 1 year, use > 6 hours per night

Weight Loss

  • Weight reduction is the first-line treatment in MILD OSA

  • Is an effective treatment for the majority of patients with mild OSA

  • Weight loss and increasing exercise seems to be beneficial for OSAS and should be recommended along with other interventions for OSAS in obese children and adolescents

  • Very low calorie diet combined with active lifestyle counseling can result in marked weight reduction and reduction in AHI

  • Can be nearly as efficacious as tracheostomy in the treatment of OSA. But, compliance with the weight-control program is a major issue when considering this form of treatment. The prognosis for weight maintenance following surgical or behavioral methods of weight reduction is also not optimistic

  • Mechanisms for OSA resolution after weight loss:

    • Reduction in nasopharyngeal collapsibility and resistance implying that calibre of upper airway increases

    • Pharyngeal and glottic function improves related to reductions in mechanical loading from parapharyngeal fat pads

    • Reduction in central adiposity and the resulting reduction in production of adipokines that act on the CNS may leading to enhanced neuromuscular control of pharyngeal calibre

    • Improvement in vital capacity, total lung volume, functional residual capacity and forced expiratory volume and this increase in lung volumes may result in increased tracheal traction on the pharynx

    • OSA improvement is NOT related to changes in nasal airflow. Absence of attenuation of OSA after weight loss may be related to presence of concomitant otorinolaringoiatriac pathology

    • Complete resolution of OSA depends on level Pcrit falls after weight loss

Positional Therapy

  • CPAP has a greater effect on improving AHI compared with positional therapy

  • Positional therapy may have better adherence than CPAP 

  • Positional therapy was better than inactive control for improving ESS and AHI

  • There were no significant differences for other clinically relevant outcomes such as quality of life or cognitive function

  • Devices designed for positional therapy include:

    • Lumbar or abdominal binders

    • Semi-rigid backpacks

    • Full-length pillows

    • A tennis ball attached to the back of nightwear

    • Electrical sensors with alarms that indicate change in position

  • At this point, no recommendations can be made with regard to positional therapy for OSAS in children

Oral Appliance Therapy

History of oral appliance therapy:

  • 1909: Emil Herbst creates Herbst appliance, which was rediscovered by Hans Pancherz in 1970s

  • 1934: Pierre Robin described a "monobloc" functional appliance that he used to pull jaw forward

  • 1979: first dental device in literature by Boraz, unsuccessful attempt to treat OSA using maxillary dental device

  • 1981: Collin Sullivan showed CPAP could reverse OSA

  • 1982: Charles F Samelson creates tongue retaining device/sleeve shown to have comparable outcomes to UPPP

  • 1983: Dr Peter George, Dr Bruce Soll created first modified nocturnal airway patency appliance (NAPA)

  • 1984: Karlheinz Meier-Ewert/Dr Heinrich Schafer created monobloc mandibular advancement appliance

  • Hoae and McNamara altered the Herbst appliance making it a removable acrylic device that was also easily adjustable

  • 1995: MAA deemed most effective in treating mild-moderate OSA

  • 2016: those who used oral appliance therapy for decades seen to have significant exacerbation in OSA level and concluded that similar to CPAP, the amount of advancement may require continuous titration during long term tx

Oral appliance designs:

  • > 60 different OAs are in the market, with notable design variations

  • Numerous designs with no gold standard types of device

  • The influence of device design on the efficacy and side-effects of OAs is almost unknown

  • Patients have poor adherence to OA if uncomfortable

  • Degree of bite changes is influenced by appliance design in addition to initial type of bite and treatment time

  • Appliances that allow mouth opening are less effective - important in severe OSA patients in supine position

  • Custom-made, titratable appliance that does not allow mouth opening is recommended

  • Pre-fabricated and “boil and bite” devices have poor retention and not suitable as test devices

  • Appliances with a soft liner are preferred by some due to ease of fit and speed of delivery; they are gentler on the teeth, particularly helpful when dealing with heavily restored teeth, veneers, or crown and bridge

  • Ball clasps can be used to assist with retention in cases of short clinical crowns or poor retention

  • Designs:

    • Tongue-retaining devices

    • Soft palate-lifting devices

    • Mandibular advancement devices

      • Mono-block

      • Hinge-based eg Somnoguard adjustable

      • Compression-based eg Herbst

      • Traction-based eg dorsal design

  • For edentulous patients, can consider:

    • Tongue-retaining devices

    • Implant-retained devices

    • Traction-based device over denture

  • Palatal lift appliances:

    • Elevate the soft palate through an adjustable acrylic button, thus preventing the tissue from vibrating during slumber

    • While this helps in reducing snoring for OSA patients, most of them have difficulty maintaining the appliances for an extended period. Consequently, palatal lift appliance use in OSA is becoming limited

  • Tongue retaining devices:

    • Draw the tongue forward in a position without regard to the mandible

    • Since these are composed of a mouthpiece covering the upper and lower arches, TRDs can be recommended for patients with insufficient dentition.

    • Though studies show that MAAs and TRDs have similar effects in apnea reduction, more than 90% of patients preferred the MADs due to better compliance

How does it work?

  • Effect of the OA on the AHI is related to the amount of mandibular protrusion

  • Success depends on ability of patient to advance jaw

  • Primary mode of action of MAA therapy is via improvement in passive pharyngeal anatomy

    • OA acutely improves the upper-airway collapsibility under passive and active conditions, without affecting muscle function, loop gain, or the arousal threshold

    • The key to success is improvement of velopharyngeal patency and increasing and stabilising the oropharyngeal and/or hypopharyngeal airway space

    • Reduction of pharyngeal closing pressure especially at velopharyngeal airway appears to be the key for mandibular advancement tx

    • Successful improvement of nocturnal oxygenation appears to be achieved when the MAA reduced the closing pressure of the passive pharynx below atmospheric pressure

    • Each 2mm mandibular advancement coincided with approx 20% improvement of the number and severity of nocturnal desaturations

  • Improves the patency of the upper airway by increasing the pharyngeal volume or size and/or reducing the pharyngeal collapsibility of the airway through muscle tone improvement in a dose-dependent manner WITHOUT systematically changing genioglossus muscle function

    • Genioglossus activities decrease with mandibular advancement during sleep which suggest little contribution of pharyngeal muscles in restoring pharyngeal patency with mandibular advancement

    • Airway collapsibility tends to improve in non-responders during the initial range of mandibular advancement (0-50%) BUT majority of improvement in airway collapsibility occurs close to the maximal possible mandibular advancement in MAA responders

    • Mandibular advancement induced improvement in pharyngeal collapsibility coupled with unchanged muscle function implies MAA tx works primarily by PASSIVELY improving pharyngeal anatomy and function

  • Pharyngeal muscle activity dramatically reduces during REM so capacity of MAA to induce major changes in muscle behaviour during REM is LIKELY LOWER compared to NREM

  • REM-predominant OSA patients have a lower complete response rate to MAA

  • MAA reduces AHI in NREM OSA more than in REM OSA

  • Response rates are lowest in supine REM OSA

  • MAA works better in NON-POSITIONAL OSA

  • Tongue moves forward en bloc in those with a low AHI following the advanced mandible, however as the severity of OSA increased, the tongue more often deformed resulting in less improvement in upper airway size

  • Alteration in soft tissue position with mandibular advancement appears impacted not only by anatomy and physiology but also mechanical factors such as mouth opening

  • Some patients whose OSA initially became worse with OA therapy may need greater advancement of the mandible

  • Studies showed many patients report a significant improvement in symptoms without equal improvement in PSG criteria

  • AADSM defined an effective oral appliance as one that advances the mandible and allows titration by the pt

  • The evidence available at present indicates that OAs successfully “cure” mild-to-moderate OSA in 40–50% of patients, and significantly improve it in additional 10–20%. They reduce, but do not eliminate snoring

  • 50–70% of patients continue to use OAs for several years

  • Their effectiveness is inferior to CPAP. It is similar to surgical procedures, but these are invasive (although not particularly dangerous) and irreversible

  • The effect of OAs on the vascular consequences of sleep apnea is not known

  • There is marked variability of individual responses to OA therapy and therefore the necessity to approach each patient on an individual basis

  • Side effects are common, but are relatively minor

  • There is a chance that the overjet and overbite will decrease which can result in a suboptimal occlusion (e.g. less occlusal contact points and a possible development of (bi)lateral crossbite in the (pre)molar region) and altered aesthetics

4 phenotypes of OSA:

  1. Impaired airway anatomy

  2. Loop gain

  3. Arousal threshold

  4. Muscle function

Factors affecting oral appliance efficacy and treatment success:

  • Baseline upper-airway anatomy/collapsibility

  • Non-anatomic trait loop gain (the ratio of the size of a response to the size of a disturbance)

  • These two traits explain the overwhelming majority (70%) of the variance in the AHI reduction

  • Responders had a less collapsible airway and lower loop gain compared with nonresponders

    • Responders to OA therapy have primarily milder anatomic deficiencies

    • Non-responders have a moderate-severe anatomic abnormality that is also accompanied by deficiencies in the non-anatomic traits (most notably loop gain)

  • Those with a better passive upper-airway anatomy/collapsibility and a low loop gain at baseline gained the greatest benefit from oral appliance therapy

Physiological goals of oral appliance therapy:

  1. Target obstructive events

  2. Reduction in AHI by way of reduced frequency and duration of apnoeas, hypopneas, RERAs

  3. Reduction in sleep fragmentation

  4. Reduction in oxygen desaturation

Symptomatic goals of oral appliance therapy:

  1. Target snoring

  2. Target sleepiness

  3. Improve QoL

  4. Possibly improve other comorbidities

Titrating the oral appliance:

  • Studies show an effective response on AHI already at a protrusion of 25% but more response is achieved when the advancement is increased to 50% or 75%

  • Most patients will receive optimal treatment in 75% advancement

  • In cases of insufficient improvement at 75% advancement, 90% can be considered

Indications for oral appliance therapy:

  • Primary snoring (OAT recommended than no therapy)

  • Adults with OSA who are intolerant of CPAP or prefer alternate therapy

  • Mild-moderate OSA and in severe OSA where CPAP fails

    • OAs have a better response when used for mild to moderate OSA who have lower BMI

  • With CPAP or positional therapy when use itself isn't totally successful

  • To reduce side effects from high pressures during CPAP

Contraindications for oral appliance therapy:

  • Rapid therapy required eg severe symptomatic OSA, sleepiness with driving

  • Severe or prolonged oxygen desaturation ie SpO2 < 70% (OAT may not improve oxygenation much)

  • Heart failure

  • Respiratory failure

  • Select dental conditions:

    • Severe TMD

    • Periodontal disease

    • Insufficient dentition for retention

    • Inadequate range of jaw motion

  • Gag reflex

  • Poor manual dexterity

  • Central sleep apnoea and/or central hypoventilation

  • Severe obesity (BMI > 35 Kg/m2)

Poor response to oral appliance therapy in obese patients with breathing related sleep disorders may be caused by:

  • Lack of mechanical influence of mandibular advancement on the velopharynx

  • Length of soft palate

  • Presence of severe oropharyngeal and hypopharyngeal narrowing

  • Increased soft tissue elasticity of the tongue may limit mechanical transmission of the mandibular advancement force to the base of tongue

Disadvantages of oral appliance therapy:

  • Short term side effects related to acclimatisation in the first few weeks of therapy:

    • Excessive salivation

    • Dental pain

    • Gingival irritation/pain and intra-oral discomfort

    • Myofascial pain and TMJ discomfort

      • TMJ discomfort are transient and decreases in intensity with continued use

      • Mandibular exercises may allow perseverance with MAA use until discomfort improves

      • Can be resolved by:

        • Correction of asymmetric mandibular advancement

        • Reducing appliance titration rate

        • Modification of the interocclusal distance

        • Addition of posterior stops to occlusal surfaces in some appliance designs

    • Passive jaw exercises and the use of morning occlusal guides are commonly used to manage both transient jaw pain and bite changes

  • Dry mouth

  • Difficulty swallowing with appliance in place

  • Long-term occlusal and dentofacial changes

    • Long-term use of an OA resulted in small but significant dental changes compared with CPAP

    • Changes in facial height and jaw relationship have been noted 6/12 into MAA use

    • Bite changes occur in almost all patients, although they tend to be minor and do generally not disturb the patients

    • Occlusal side effects are typically the most frequently experienced side effect and appear insidiously, they are rarely a cause for discontinuation of OA by patients

  • Dental changes (progressive in nature with ongoing OA use):

    • Dental side effects of OA treatment are a product of protruding the mandible to achieve a therapeutic effect rather than specific appliance design

    • Decrease in overbite (2mm), overjet (2mm) and mandibular crowding

    • Increase in mandibular intercanine and intermolar width resulting in widening of mandibular dental arch

      • Overbite was found to decrease less with time

      • Overjet was found to decrease progressively and continues at a constant rate

    • Proclination of lower incisors

    • Retroclination of upper incisors

    • Occlusal alterations to posterior teeth

    • Bilateral anterior crossbite in the (pre)molar region and posterior open bite on > 2 mandibular teeth resulting in anterior-posterior occlusal change

    • Decrease in number of occlusal contact points in the (pre)molar region

    • Shift in molar and cuspid occlusion from class I to class III or a shift from class II to class I or III

    • Bite changes

      • Degree of bite changes is influenced by appliance design in addition to initial type of bite and treatment time

      • Even very low applied forces, if applied for a sustained amount of time (such as for several hours during nighttime wear of an appliance) will result in tooth movement 

      • Permanent bite changes can arise from tooth movement or jaw joint repositioning that may or may not be reversible on discontinuing oral appliance

      • The design of the MAA might influence the type and magnitude of orthodontic side effects during treatment for snoring and OSA

        • A deep bite and soft elastomeric monoblock device with full occlusal coverage has been found to produce fewer reductions in overjet than a hard acrylic monoblock

        • Advancements of the mandible of < 6 mm related to a high chance of small overjet reductions

        • Larger vertical displacements of the mandible tended to relate to small reductions in overjet

        • Patients with normal occlusion and mild disease could try a soft elastomeric device with an advancement < 6 mm and a low-to-moderate vertical displacement to diminish the risks of orthodontic side effects

      • Symptoms of nasal congestion before MAA treatment were related to smaller risks of overjet changes among the frequent users

        • This might be explained by slight differences in compliance rates between the patients; those who suffered from nasal congestion might have found the appliance difficult to wear when this symptom disturbed them

        • On the other hand, nasal congestion might cause the lips or the mouth to open during sleep with the device or during the daytime without the device; this might in turn reduce the horizontal forces on the maxillary front teeth and result in smaller reductions in overjet by the device. This suggestion is supported by the finding that a reduction in the force exerted by the lips has been related to more maxillary incisor proclination in untreated subjects

      • Certain jaw exercises might help to relieve stiffness of the masticatory muscles and accelerate the repositioning of the mandible to the normal position after a night of appliance use

      • Jaw exercises may also inhibit or minimize the occlusal functional changes in predisposed patients

      • If not reversible, restorative or orthodontic intervention may be needed

    • Loosening of teeth

  • Does not tend to reduce daytime sleepiness in severe OSA group as much as CPAP

  • In milder OSA group unclear if daytime sleepiness is significantly reduced

    • Milder OSA patients generally have less collapsible airways and pharynx will increase more along the whole of its length

Benefits of oral appliance therapy:

  • Improves sleepiness

  • Decrease AHI, although to a lesser extent than CPAP

  • Can improve blood pressure modestly, like CPAP

  • Can improve arousal index, oxygen saturation, REM sleep duration, snoring

  • CPAP+MAA is more effective than placebo in improving QoL symptoms and subjective BUT NOT OBJECTIVE sleepiness with neither being better 

  • Blood pressure:

    • No response to CPAP whereas MAA improved NOCTURNAL diastolic BP but no significant response in hour by hour mean BP with either MAA or CPAP

    • Significant portion of non-dipper subjects with MAA regained their normal nocturnal dip in BP but not with CPAP or placebo

  • Compared with placebo, CPAP tx resulted in no greater improvement than MAA in measures of daytime function (sleepiness, executive function, quality of life) or was found to have only a very slight advantage (mood) but may relate to differences in treatment adherence with an otherwise superior CPAP treatment response being moderated by relatively poor adherence

  • Despite positive responses to both CPAP and MAA treatments there is a significant residual neurobehavioural deficit likely relating to poor usage of CPAP and lesser efficacy of MAA

  • Boil and bite thermoplastic design could reduce AHI but poorly tolerated and no retention

  • Both oral appliance therapy and CPAP may be equally effective in reducing the risk of fatal cardiovascular events in patients with severe OSA

Predictors of MAA treatment success:

  • Younger age

  • Lower BMI

  • Smaller neck circumference

  • Mandibular retrognathism and large OB, OJ

  • Greater upper anterior face height

  • Female

  • Low baseline AHI

  • Low loop gain

  • Moderate pharyngeal collapsibility

  • Position dependent OSAH BUT none are sufficiently discriminatory

  • Lateral cephalograms showing (although association is weak):

    • Retrognathic mandible deficiency (i.e. smaller angle between the lines

      connecting Sella with Nasion and Nasion with point B [SNB])

    • Shorter soft palate

    • Low set hyoid bone

    • Larger intermaxillary discrepancy (i.e. higher angle between

      the lines connecting point A with Nasion and point B with

      Nasion [ANB])

Predictive tools:

  • MRI computational manipulation of scans - too expensive

  • Drug induced sleep endoscopy - effective but expensive and intrusive

  • Titrating MAA during sleep studies

  • Testing mandibular advancement with cheap device but thermoplastic device did not predict success with customised MAA

  • Adjustable thermoplastic MAA

  • In prediction modelling, age, baseline AHI, and anthropometric variables were predictive of MAA treatment outcome but not OSA phenotype. Gender was not associated with treatment outcome

  • Demographic, anthropometric, and PSG data only weakly inform about MAA efficacy, supporting the need for alternative objective prediction methods to reliably select patients for MAA treatment

  • Sutherland study found patient characteristics of younger age and less obesity (but not gender) are associated with treatment response, but these prediction models do not have sufficient accuracy for clinical practice, and hence alternative prediction methods are needed, particularly as up to a quarter of severe patients could be completely treated by this therapy alone

Predictors of adherence:

  • Related mostly to improvement in symptoms but efforts to predict OA adherence have so far been unsuccessful

  • OA adherence highest in thinner younger subjects with few or no nasal obstructions

  • Although less effective than CPAP, successfully titrated MAA is very effective at reducing the AHI and was associated with a higher reported compliance

  • Deterioration of success possibly due to loosening and adaptation of soft tissue structures and musculature of upper airway as a result of long-term overnight advancement as well as age related reduction in genioglossus muscle tone

  • The most common reasons for discontinued use reported by patients were:

    • Unable to adapt to the appliance (62%)

      • Highest percentage of dropouts (55%) occurred in the first year of appliance use

      • This pattern of withdrawal from therapy can also be found in CPAP adherence studies

    • Pain in the temporomandibular joint (38%)

    • Ineffectiveness (35%). One-third of patients experience no therapeutic benefit

  • The most common factors associated with continued usage were:

    • Effectiveness (100%)

    • Ease of use

    • Overall long-term efficacy of OA treatment is fairly good - 76% of patients report using their OA after 1 year and 62% of patients after 4 years

Factors affecting favourable outcome of MAA therapy:

  • Younger age

  • Less obese

  • Mild OSA

  • Certain craniofacial characteristics:

    • Mandibular retrognathism

    • Larger OB, OJ

    • Greater upper anterior face height

Long-term efficacy of oral appliance:

  • There is uncertainty about which patients will respond to this therapy in terms of apnoea reductions, decreased sleepiness and other symptoms, and reduced risk for future impaired health

  • Efficacy fairly stable up to 10 yrs, but it probably declines in the real-life long-term perspective

    • The natural development of the disease usually results in a deterioration in AHI 

    • Aging increases AHI

    • Ability of pt to keep airways patent changes continuously

    • Bite changes may also reduce advancement of jaw therefore reduce efficacy

  • Effectiveness declines with patients discontinuing treatment because of poor subjective treatment effect or side-effects, or poorer outcomes in follow-up sleep apnea recordings

  • Supine-predominant OSA patients had lower treatment response rates than non-positional OSA (e.g., 36% vs. 59% for AHI < 10/h)

  • REM-predominant OSA showed a lower response rate than either NREM or non-stage dependent OSA

  • An average 50% reduction in total AHI was observed with similar improvements across NREM and REM supine and non-supine sleep

  • MAA reduced apnea and hypopnea duration and arousal index and increased minimum oxygen saturation and REM sleep duration

  • MAA reduced AHI across all sleep stages, with the exception of increased AHIREM in NREM-predominant patients

  • In stage-independent OSA, MAS reduced AHINREM more than AHIREM

  • REM-predominant OSA showed lower response rate than other sleep stage phenotypes

  • Complete resolution of REM-OSA was only observed in 12% of patients, significantly lower than other phenotypes (42% NREM and 32% non-stage dependent)

  • REM-predominant patients were more likely female and showed more obesity

  • MAS reduced AHI in both supine and lateral body position, with the exception of increased AHINon-Supine in Supine-isolated patients

  • In non-positional OSA, MAS reduced AHINon-Supine more than AHISupine

  • MAS did not change supine or non-supine sleep duration

Patients with OSA referred for oral appliance therapy require specific evaluation related to TMD:

  • Most common TMD diagnosis is myofascial pain with and without limited mouth opening and arthralgia (50%)

  • Many patients may not be aware they have TMD, and thus TMD pain may be manifested with oral appliance therapy who have not been diagnosed with TMD in the past

  • Appliance did not cause any significant change to TMJ morphology over time period

    • Patients who did not develop pain had condyles within physiological limits of TMJ movements

    • If translation of the condyle surpasses physiologic limits, it may result in articular pain possibly due to distension of the posterior attachment of the articular disc or the TMJ articular capsule

  • Support therapy for TMD should be provided to patients using MAA

Use of occlusal splint in apneic patient:

  • Is associated with a risk of aggravation of respiratory disturbances

  • Can cause an increase in AHI by more than 50%, RDI by more than 30%

  • Can exacerbate snoring

Oral appliance effects on snoring:

  • Effective control CPAP > OA > placebo

  • Persistent snoring during OA tx related to insufficient apnoea control and poor adherence to tx

  • Little research focused on snoring as difficult to measure sounds and less evidence of snoring being related to longer term negative health outcomes

  • Patients are more interested in psychosocial outcomes produced by snoring tx

Remotely Controlled Mandibular Positioner (RCMP)

  • RCMP might be a promising instrument for predicting OA treatment outcome and targeting the degree of mandibular advancement needed

  • Using RCMP, it might be possible to protrude the mandible progressively during sleep under PSG observation until respiratory events are eliminated without disturbing sleep or arousing the patient

  • Effective target protrusive position (ETPP) has been shown to significantly be associated with success of OA therapy in studies

Positive Airway Pressure Therapy

Mechanism of action:

  • Prevents respiratory events from upper airway collapse (apnoeas and hypopneas)

  • Maintains a positive pharyngeal transmural pressure so that the intraluminal pressure exceeds the surrounding pressure and by increasing end expiratory lung volume

The application of CPAP:

  • CPAP is a way of delivering a set pressure during the breathing cycle. It is measured in centimeters of water pressure (cm H2O)

  • Recommendations state that the minimum starting CPAP should be 4 cm H2O in adult patients and should be titrated to the lowest possible pressure at which apneic/hypopneic events are eliminated, to a maximum pressure of 20 cm H2O

  • Maintains PEEP (Positive End-Expiratory Pressure is the pressure in the alveoli above atmospheric pressure at the end of expiration)

  • Can decrease atelectasis (incomplete inflation of the lung)

  • Increases the surface area of the alveolus

  • Improves V/Q matching (a V/Q mismatch is when areas of the lung receive blood flow but no oxygen or vice versa), and hence, improves oxygenation

  • CPAP differs from bilevel positive airway pressure (BiPAP) where the pressure delivered differs based on whether the patient is inhaling or exhaling

    • These pressures are known as inspiratory positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP)

    • In CPAP no additional pressure above the set level is provided, and patients are required to initiate all of their breaths (which differs from the IPAP component of BiPAP)

  • The forced air delivered by CPAP helps to keep the airways patent and prevents collapse

  • Compliance is a recognised issue

CPAP use in children with OSA:

  • Nasal CPAP is effective in the treatment of both symptoms and PSG evidence of OSA even in young children

  • BUT adherence can be a major barrier to effective CPAP use

    • For this reason, CPAP is NOT recommended as first-line therapy for OSAS in children when adenotonsillectomy is an option

    • But it is useful in children who do not respond adequately to surgery or in whom surgery is contraindicated

  • Objective assessment of CPAP adherence is important because parental estimates of use are often inaccurate

  • If the patient is non-adherent, then attempts should be made to improve adherence by:

    • Addressing adverse effects by using behavior modification techniques

    • Treating with alternative methods

  • A study noted that CPAP pressures change over time in children, presumably because of growth and development. Therefore, it is recommended that CPAP pressures be periodically reassessed in children

Types of PAP:

  1. CPAP (continuous single pressure)

  2. APAP (auto-titrating positive airway pressure)

  3. BPAP (bi-level positive airway pressure) or VPAP (variable positive airway pressure) - 2 distinct pressure settings for inhalation (IPAP) and exhalation (EPAP)

  4. Nasal EPAP

  5. ASV (adaptive servo ventilation)

    • Algorithms maintain positive pressure, respiratory patterns and oxygen levels

    • Used for global respiratory insufficiency caused by COPD

Sensors for respiratory monitoring:

  • Airflow

    • Oronasal thermal flow

    • Nasal pressure transducer

  • Respiratory effort

    • Thoracoabdominal belt

  • Oxygen saturation

    • Pulse oximetry

CPAP masks:

  • Nasal

    • Is the gold standard for OSA therapy

  • Nasal pillow

  • Nasal cradle

  • Full face mask

  • Oral mask

  • Oronasal mask

    • Oronasal masks are associated with a higher CPAP pressure, higher residual AHI, and poorer adherence than nasal masks

    • Oronasal masks push chin backwards

    • Oronasal masks may allow mouth opening

    • Oronasal masks applied positive pressure to the oral compartment neutralising the pressure to the pharynx

Side effects of PAP:

  • Congestion

  • Rhinorrhoea

  • Sinus infection

  • Nosebleeds

  • Nasal dryness

  • Dry mouth

  • Sore throat

  • Abdominal distension (aerophagia)

  • Otic barotrauma (increase in middle ear pressure) as a result of excessive self-titration of CPAP therapy

  • Pneumocephaly, pulmonary barotrauma, intraocular hypertension, and subcutaneous emphysema

  • Claustrophobia

  • Eyes irritation

  • Difficulty breathing the pressurised flow

  • Sore skin areas over the nose bridge or upper lip related to the mask interface

  • Dentofacial changes

    • Nasal CPAP may change craniofacial form and may alter the relationship between the dental arches

    • Long-term nasal CPAP may cause a retroclination of the maxillary incisors and a decrease in the number of occlusal contact points

    • As nasal CPAP is administered through a tight-fitted (nose) mask, it could be hypothesized that the pressure of this mask results in palatally directed forces on the frontal part of the upper dental arch

  • Machine noise

  • Loss of intimacy

  • Cost of treatment

  • Inconvenience

Indications for PAP:

  • OSA

  • NICU to treat pre-term infants

  • Congestive heart failure

  • Some respiratory infections in children

Contraindications for PAP:

  • Uncooperative or extremely anxious patients

  • Reduced consciousness and inability to protect the airway

  • Unstable cardiorespiratory status or respiratory arrest

  • Poor respiratory drive

  • Trauma or burns involving the face

  • Facial, oesophageal or gastric surgery

  • Air leak syndrome (pneumothorax with bronchopleural fistula)

  • Copious respiratory secretions

  • Severe nausea with vomiting

  • Severe air trapping diseases with hypercarbia, asthma or COPD

  • Not spontaneously breathing

Benefits of CPAP:

  • Reduced sleepiness

  • Success is defined as ≥ 50% AHI reduction AND < 20 AHI score (mild-moderate)

  • CPAP has considerably higher probability of having the strongest association with systolic BP reduction than MAA, whilst both CPAP and MAA had similar reduction in diastolic BP

    • The more the CPAP is used, the more SBP, DBP benefit there is

    • Association of CPAP with reductions in SBP and DBP likely to be greater in patients using CPAP for longer periods at night or in those with higher initial baseline BP levels

    • A 1-hour-per-night increase in mean CPAP use was associated with an additional reduction in SBP and DBP

Benefits of using APAP in the home setting:

  • Lower cost

  • Reduced time away from home

  • Faster initiation of treatment

  • Greater access to care

Disadvantages of using APAP in the home setting:

  • Inadequate patient education

  • Inability to identify and rectify problems related to mask fit, leak or other PAP-related  issues on the night of APAP use

Benefits of in-lab PAP titration:

  • Providing education by a trained sleep technologist

  • Real-time visual identification of efficacy of therapy

  • Ability to provide immediate interventions to make PAP treatment more comfortable  for the patient

Disadvantages of in-lab PAP titration:

  • The  need  for  an  overnight  stay  away  from  home  at  the  testing facility

  • Associated costs

  • Patient time

  • Potential delay in therapy initiation

When CPAP is not beneficial:

2 recent RCTs (Sleep Apnea Cardiovascular Endpoints [SAVE] and Randomized Intervention with CPAP in Coronary Artery Disease and Sleep Apnea [RICCADSA]) reported that there was no cardiovascular benefit of treatment using CPAP in patients with OSA who had pre-existing cardiovascular disease and minimal sleepiness

American Academy of Sleep Medicine PAP Clinical Practice Guideline:

  • Use PAP compared to no therapy to treat OSA in adults with:

    • Excessive sleepiness

    • Impaired sleep related QoL

    • Co-morbid hypertension

  • There is insufficient and inconclusive findings regarding the impact of PAP therapy on incident CV events and mortality and so no recommendation is made regarding the use of PAP based on reduced incident CV events and mortality

  • Positive airway pressure therapy be initiated using either APAP at home or in-lab PAP titration in adults with OSA and no significant comorbidities

    • There is no clinically significant differences in adherence, sleepiness, or QoL between APAP at home and in-laboratory PAP titration

    • The majority of well-informed adult patients with OSA and without significant comorbidities would prefer initiation of PAP using the most rapid, convenient and cost-effective strategy

  • Clinicians use either APAP or CPAP for ongoing treatment of OSA in adults

    • The benefits and harms of APAP and CPAP are similar and so the balance of effects does not favor either intervention

    • The main potential benefit of APAP to patients is the ability to automatically adjust pressure requirements over time in response to acute and chronic changes (e.g. alcohol consumption, body position or weight changes)

  • Clinicians use CPAP or APAP OVER BPAP in the routine treatment of OSA in adults

    • The main potential benefit of BPAP over CPAP or APAP is improved  comfort by lowering the pressure during exhalation, which may then  increase adherence

    • The potential harms of BPAP over CPAP or APAP are a sub-optimally low expiratory pressure level that fails to prevent the occurrence of obstructive breathing events and the higher cost of BPAP

    • There  is  a  small  subset  of  patients  that  require PAP treatment with pressures higher than 20 cm H2O, which CPAP units are not typically capable of delivering. In these  situations,  BPAP  devices  may  be  needed

    • In addition, for specific patients who are unable to tolerate CPAP or APAP due to high pressure requirements and despite the use of modified pressure profiles, a trial of BPAP may be offered

  • Educational interventions be given prior to initiation of PAP therapy in adults with OSA

    • Behavioral and/or troubleshooting interventions be given during the initial period of PAP therapy in adults with OSA

    • Educational interventions: Interventions focused primarily on providing information prior to initiation of PAP about what OSA  is, its downstream  consequences, what  PAP therapy is, and the potential benefits of PAP therapy

    • Behavioral  interventions: Interventions focused on behavior change prior  to and during the initiation and subsequent use of PAP therapy using  strategies such as CBT or motivational enhancement

    • Troubleshooting interventions: Interventions focused on close patient communication to identify PAP-related problems and to initiate potential solutions during the initial period of PAP therapy

  • Clinicians use telemonitoring-guided interventions during the initial period of PAP therapy in adults with OSA

    • Telemonitoring  includes  the  remote  monitoring  of  PAP  parameters  such  as  PAP  use, residual OSA severity, unintentional  mask  leaks, and  PAP settings during treatment initiation and follow-up.

  • Clinicians should generally use NASAL or INTRANASAL mask interfaces over  oronasal or oral interfaces. However, individual patient factors or preferences vary;  therefore, the mask interface that minimizes side effects and optimizes efficacy and adherence should be used

  • Humidified PAP:

    • Reduces some side effects (dry mouth/nose, nasal congestion, nose bleeds, sore throat etc)

    • No clinical significant improvement in adherence, QoL, sleepiness, increase ongoing cost, maintenance

CPAP vs MAA:

  • CPAP gold standard in reducing AHI and improving QoL, ESS and BP however CPAP does not appear to be more effective at achieving better health outcomes

  • Effects of MAA and CPAP on health related QoL, cognitive perfusion, BP were also similar but CPAP may produce better outcome than OA

  • Minimum acceptable CPAP compliance threshold is 4 hrs/night

  • CPAP failure rates 29% - 83% depending on study population

  • Higher efficacy of CPAP offset by greater MAA compliance

    • MAA compliance 6.5 hrs/night vs 5.2 hrs/night with CPAP

    • Good support for hypothesis that MAA and CPAP have similar clinical effectiveness due to greater MAA compliance achieving net similar AHI reduction

    • Lower CPAP compliance results in no differences with MAA in QoL, cognitive, or functional outcomes

    • Sleep medicine professionals should monitor treatment compliance and offer patients non-compliant with CPAP an oral appliance for treatment of OSA

    • No significant difference between 24hr mean systolic or diastolic BP or change in BP

  • MAA had significantly lower night time diastolic BP

  • MAA tx had significantly more apnoeas and hypopneas

  • CPAP subjects had significantly more in % REM sleep

  • Daytime sleepiness is better treated with CPAP than with MAA in patients with severe OSA

  • In patients with milder OSA it is unclear whether daytime sleepiness is significantly reduced

  • MAAs are effective, but their efficacy is more variable than that of CPAP

Rapid Maxillary Expansion in Children

  • An orthodontic procedure designed to increase the transverse diameter of the hard palate by reopening the midpalatal suture by means of a fixed appliance with an expansion screw anchored on selected teeth

  • After 3 to 4 months of expansion, a normal mineralized suture is built up again

  • The procedure is typically used only in children with maxillary constriction and dental malocclusion

  • Results in significant improvement in signs and symptoms of OSAS as well as PSG parameters

  • Holds promise as an alternative treatment of OSAS in children. However, data are insufficient to recommend its use at this time

Surgery

Indications for surgery in adults (ASA):

  • Failed compliance with/intolerance of device therapy

  • Significant complications of device therapy

  • Patient favours surgery and declines all other options

  • Favourable anatomy for surgery

  • As an adjunct to improve CPAP or oral appliance effectiveness

Indications for surgery in children:

  • Adenotonsillar hypertrophy

Surgical therapies:

  • Procedures to improve nasal patency and breathing eg polypectomy, turbinate reduction, septoplasty

    • Will not improve OSA

    • May improve nasal breathing, CPAP tolerance and compliance

  • Procedures to improve retropalatal obstruction (UPPP, UPF, tonsillectomy, adenoidectomy)

    • Success rate 40% based on reduction of AHI and RDI

    • UPPP is not recommended

  • Procedures to improve tongue-base and hypopharyngeal obstruction

    • Tongue-base, temperature-controlled radiofrequency

      • Rarely results in significant OSA improvement

      • Often performed as an adjunct to other hypopharyngeal procedures

    • Tongue-base suture suspension

      • Success rate variable

      • Often performed in conjunction with the UPPP to maximise outcomes

    • TORS for tongue-base reduction

      • Success rate 54% based on reduction of AHI and resolution of daytime sleepiness

    • Posterior midline glossectomy

      • Success rate variable, 25-83% based on AHI reduction

    • Genioglossus advancement

      • Success rate variable, 23-77%, based on AHI reduction

    • Maxillomandibular advancement

      • Around 75-100% based on AHI reduction

  • Hypoglossal nerve stimulation

    • Safe and effective for CPAP refractory OSA, high compliance and significantly improves subjective and objective outcomes of sleep

    • Targets pharyngeal tone and stimulates genioglossus protrusion to maintain airway patency 

    • Delivers safe levels of electrical stimulation to the hypoglossal nerve via a stimulation lead having a distal cuff electrode

    • Stimulation is delivered synchronous with inspiration as detected by respiration sensing leads using bio-impedance  

    • Electrical stimulation of genioglossus causes tongue protrusion and stiffening of anterior pharyngeal wall

    • Contraction of genioglossus muscle can be achieved by electrically stimulating its motor nerve

    • HGNS can decrease OSA and improve severity of oxyhaemoglobin desaturation without arousing patients from sleep

    • Cohort that would most benefit from therapy is:

      • BMI < 35 (low to moderate)

      • AHI 20-50

      • Non-concentric collapse of retropalatal airway

    • Discontinuation of HGNS did not cause patients to immediately revert to baseline AHI/ODI but long term discontinuation does - potential to modify the disease course of OSA

    • Complications generally uncommon and benign

    • Common adverse events of HGNS:

      • Most serious complication is device migration

      • Device malfunction

      • Pain (classified as non-serious, managed by analgesics)

      • Tongue abrasion as device stimulates the genioglossus to protrude the tongue against the teeth (resolve by reprogramming the device or use a tooth guard)

      • Abnormal sensations

      • Paresthesias

      • Change in saliva flow and lip weakness

      • No mention of dysphagia (common in traditional upper airway surgery)

Medications

  • Topical steroids may ameliorate mild OSAS. However, the clinical effects are small

  • Intranasal steroids may be considered for treatment of mild OSAS (defined as an AHI < 5/hr)

  • Steroids should not be used as the primary treatment of moderate or severe OSAS 

Non-Invasive Therapy (NIV)

  • In patients with amyotrophic lateral sclerosis WITHOUT severe bulbar dysfunction, NIV improves survival with maintenance of and improvement in quality of life

  • In patients WITH severe bulbar impairment, NIV improves sleep-related symptoms, but is unlikely to confer a large survival advantage